3rd May 2007 07:01
Bespak PLC03 May 2007 Bespak plc Strong trading in the 52 weeks to 28 April 2007 Bespak plc (LSE:BPK), a leader in devices for inhaled drug delivery andanaesthesia, anticipates that reported performance in the year ending 28 April2007 will be in line with or will marginally exceed expectations with strongtrading in both its Inhaled Drug Delivery and Anaesthesia & Respiratory Carebusiness segments. Inhaled Drug Delivery continued the strong organic growth reflected in the firsthalf with record sales of CFC-free valves and dry powder inhalers. Thetransition in the US market to CFC-free asthma formulations progresses moresuccessfully than anticipated. Bespak has also won a number of new valve anddose counter development programmes during the year. Bespak has continued tobenefit from demand for the Exubera(R) inhaler to support its global launch,although there are uncertainties about short- to medium- term sales volumes. The good performance in Anaesthesia & Respiratory Care reflected the first fullyear of the King Systems acquisition, and reflected the same growth trajectoryseen in the first half. King Systems is a leading supplier of disposablebreathing circuits, masks and laryngeal tubes, mainly sold to hospitals in theUS. Last month Bespak announced the two-step acquisition of Emergent RespiratoryProducts of Irvine, California. This acquisition is highly complementary to Kingand will expand Bespak's access to the growing pre-hospital emergency medicinemarket segment where Bespak's existing airway management products haveconsiderable potential. Bespak will report its preliminary results on 11 July 2007. For further information please contact: BespakMark Throdahl, Chief Executive Tel: +44 (0)1908 552600Jonathan Glenn, Group Finance Director MaitlandBrian Hudspith or Liz Morley Tel: +44 (0)20 7379 5151 Bespak plc is a leader in specialty medical devices, developing delivery systemsfor the pharmaceutical industry and disposable airway management products forcritical care settings. The company develops and manufactures metered dose inhalers, actuators,compliance aids, dry powder devices, disposable facemasks, breathing circuits,and laryngeal tubes. The group holds the 2005 Frost & Sullivan Award forTechnology Innovation and has facilities in King's Lynn and Milton Keynes in theUK, in Indianapolis, Indiana and Kent, Ohio, in the US, and in Mumbai, India.Bespak is a public company quoted on the full list of the London Stock Exchange(LSE: BPK). This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
CSRT.L